Vincamine ameliorates hepatic fibrosis via inhibiting S100A4‐mediated farnesoid X receptor activation: based on liver microenvironment and enterohepatic circulation dependence
Vincamine significantly reverses hepatic fibrosis via inhibiting S100A4 involved in the crosstalk between macrophages and HSCs, and by activating the FXR-TGR5 pathway. Targeting the S100A4-mediated FXR dependence on modulating the liver environment may be the key target of vincamine in inhibiting hepatic fibrosis.
Authors
- Ji‐Xing Nan (ORCID: https://orcid.org/0000-0002-6221-4309)
- Li‐Hua Lian (ORCID: https://orcid.org/0000-0002-6957-1317)
- Sheng Liu (ORCID: https://orcid.org/0000-0002-4058-4413)
- Yan‐Ling Wu (ORCID: https://orcid.org/0000-0001-9014-3264)
- Chenyu Wang (ORCID: https://orcid.org/0000-0001-7135-7662)
- Xu Dai
- Zhenyu Cui (ORCID: https://orcid.org/0000-0002-7548-3866)
- Jia Guo (ORCID: https://orcid.org/0000-0002-3701-8867)
Institutions
- Yanbian University (CN)
- Jilin Vocational College of Industry and Technology (CN)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1111/bph.17471
- Citations
- 5
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 7.79
Funders
- Natural Science Foundation of Jilin Province
- National Natural Science Foundation of China
- People's Government of Jilin Province